Nature Reviews Drug Discovery 6, 29-40 (January 2007) | doi:10.1038/nrd2201

There is a Correspondence (November Issue 2007) associated with this article.

Focus on: Antibacterials

Drugs for bad bugs: confronting the challenges of antibacterial discovery

David J. Payne1, Michael N. Gwynn1, David J. Holmes1 & David L. Pompliano1  About the authors


The sequencing of the first complete bacterial genome in 1995 heralded a new era of hope for antibacterial drug discoverers, who now had the tools to search entire genomes for new antibacterial targets. Several companies, including GlaxoSmithKline, moved back into the antibacterials area and embraced a genomics-derived, target-based approach to screen for new classes of drugs with novel modes of action. Here, we share our experience of evaluating more than 300 genes and 70 high-throughput screening campaigns over a period of 7 years, and look at what we learned and how that has influenced GlaxoSmithKline's antibacterials strategy going forward.

Author affiliations

  1. Infectious Diseases Centre of Excellence for Drug Discovery, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, USA.

Correspondence to: David L. Pompliano1 Email:

Published online 8 December 2006


These links to content published by NPG are automatically generated.


Genetic strategies for antibacterial drug discovery

Nature Reviews Genetics Review (01 Jun 2003)

Membrane lipid homeostasis in bacteria

Nature Reviews Microbiology Review (01 Mar 2008)

See all 15 matches for Reviews


Drug discovery Know your chemical space

Nature Chemical Biology News and Views (01 Jul 2010)

Genome sequencing Panspermia, spores and the Bacillus subtilisgenome

Nature News and Views (20 Nov 1997)